NO20074173L - Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand - Google Patents

Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand

Info

Publication number
NO20074173L
NO20074173L NO20074173A NO20074173A NO20074173L NO 20074173 L NO20074173 L NO 20074173L NO 20074173 A NO20074173 A NO 20074173A NO 20074173 A NO20074173 A NO 20074173A NO 20074173 L NO20074173 L NO 20074173L
Authority
NO
Norway
Prior art keywords
alkyl
aryl
formula
novel
gamma receptor
Prior art date
Application number
NO20074173A
Other languages
English (en)
Norwegian (no)
Inventor
Zbigniew Majka
Tomasz Stawinski
Katarzyna Rusin
Krzysztof Kurowski
Katarzyna Matusiewicz
Daniel Sulikowski
Piotr Kowalczyk
Dominic Kludkiewicz
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of NO20074173L publication Critical patent/NO20074173L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36One oxygen atom
    • C07D263/38One oxygen atom attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20074173A 2005-01-19 2007-08-14 Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand NO20074173L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL372332A PL372332A1 (pl) 2005-01-19 2005-01-19 Nowe związki, pochodne kwasu 3-fenylopropionowego
PCT/EP2006/050234 WO2006077206A1 (en) 2005-01-19 2006-01-17 New 3-phenylpropionic acid derivatives and their use as ppar- gamma rezeptor liganden

Publications (1)

Publication Number Publication Date
NO20074173L true NO20074173L (no) 2007-08-14

Family

ID=36046977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074173A NO20074173L (no) 2005-01-19 2007-08-14 Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand

Country Status (25)

Country Link
US (2) US7309791B2 (da)
EP (1) EP1874745B1 (da)
JP (1) JP2008527021A (da)
KR (1) KR100889447B1 (da)
CN (1) CN101098862A (da)
AT (1) ATE448214T1 (da)
AU (1) AU2006207492B8 (da)
BR (1) BRPI0606501A2 (da)
CA (1) CA2590575C (da)
CY (1) CY1109678T1 (da)
DE (1) DE602006010353D1 (da)
DK (1) DK1874745T3 (da)
ES (1) ES2336358T3 (da)
HR (1) HRP20090647T1 (da)
IL (1) IL183564A0 (da)
MX (1) MX2007008114A (da)
NO (1) NO20074173L (da)
PL (2) PL372332A1 (da)
PT (1) PT1874745E (da)
RS (1) RS51215B (da)
RU (1) RU2369602C2 (da)
SI (1) SI1874745T1 (da)
UA (1) UA89940C2 (da)
WO (1) WO2006077206A1 (da)
ZA (1) ZA200705889B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
EP1951692B1 (en) * 2005-11-07 2010-08-18 Irm Llc Oxazole and thiazole ppar modulator
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
EP2380884B1 (en) * 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
RS63074B1 (sr) * 2014-07-03 2022-04-29 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552125A (en) 1975-06-07 1979-09-05 Lilly Industries Ltd 2-acylamino oxazoles
JPS58125039A (ja) 1982-01-21 1983-07-25 Konishiroku Photo Ind Co Ltd 写真用2当量イエロ−カプラ−
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
EP0751943A1 (en) 1994-03-12 1997-01-08 Yuhan Corporation Triazole compounds and processes for the preparation thereof
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20010030881A (ko) 1997-10-02 2001-04-16 가와무라 요시부미 아미도카르복실산 유도체
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
ES2215719T3 (es) 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
FR2808798A1 (fr) 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
EP1414785A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
JP2005503377A (ja) 2001-07-30 2005-02-03 ノボ ノルディスク アクティーゼルスカブ 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
PL371841A1 (pl) * 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego

Also Published As

Publication number Publication date
IL183564A0 (en) 2007-09-20
WO2006077206A1 (en) 2006-07-27
CY1109678T1 (el) 2014-08-13
CA2590575A1 (en) 2006-07-27
RS51215B (sr) 2010-12-31
HRP20090647T1 (hr) 2010-01-31
US20070161799A1 (en) 2007-07-12
UA89940C2 (en) 2010-03-10
AU2006207492B2 (en) 2009-03-05
CA2590575C (en) 2010-09-21
EP1874745B1 (en) 2009-11-11
ZA200705889B (en) 2009-03-25
US7629370B2 (en) 2009-12-08
KR20070097112A (ko) 2007-10-02
DE602006010353D1 (de) 2009-12-24
AU2006207492B8 (en) 2009-03-26
EP1874745A1 (en) 2008-01-09
PL372332A1 (pl) 2006-07-24
AU2006207492A1 (en) 2006-07-27
PL1874745T3 (pl) 2010-03-31
RU2007131423A (ru) 2009-02-27
SI1874745T1 (sl) 2010-02-26
DK1874745T3 (da) 2009-12-21
ATE448214T1 (de) 2009-11-15
PT1874745E (pt) 2010-01-13
US7309791B2 (en) 2007-12-18
US20060160868A1 (en) 2006-07-20
MX2007008114A (es) 2007-08-02
JP2008527021A (ja) 2008-07-24
KR100889447B1 (ko) 2009-03-24
CN101098862A (zh) 2008-01-02
ES2336358T3 (es) 2010-04-12
RU2369602C2 (ru) 2009-10-10
BRPI0606501A2 (pt) 2009-06-30

Similar Documents

Publication Publication Date Title
MY142807A (en) Benzimidazole derivative and use thereof.
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20074173L (no) Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand
CY1112800T1 (el) Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
MY156747A (en) Isoxazolo-pyridine derivatives
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20050141L (no) Prodrugs av imidazolderivater for anvendelse som protonpumpeinhibitorer ved behandlingen av f.eks. peptisk ulcus
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
NO20076000L (no) Aminosyrederivater
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser
NO20073736L (no) Nye 3-fenylpropionsyrederivater for behandlingen av diabetes
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
NO20080940L (no) Ikke-steroide forbindelser anvendbare som glukokortikoide reseptor modulatorer
NO20064806L (no) Formamidderivater anvendelige som adenoceptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application